Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Ovarian Neoplasms

  Free Subscription


1 Am J Obstet Gynecol
1 BMC Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
2 Gynecol Oncol
1 Hum Pathol
1 Obstet Gynecol
1 Oncol Rep

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Obstet Gynecol

  1. VETTER MH, Smrz SA, Copeland LJ, Cohn DE, et al
    Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
    Am J Obstet Gynecol. 2020 May 23. pii: S0002-9378(20)30569.

    BMC Cancer

  2. TSUYOSHI H, Orisaka M, Fujita Y, Asare-Werehene M, et al
    Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
    BMC Cancer. 2020;20:467.
    PubMed         Abstract available

    Cancer Lett

  3. CAUMANNS JJ, van Wijngaarden A, Kol A, Meersma GJ, et al
    Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer Lett. 2019 Jul 15. pii: S0304-3835(19)30400.
    PubMed         Abstract available

    Cancer Res

  4. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    PubMed         Abstract available

    Clin Cancer Res

  5. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    PubMed         Abstract available

    Gynecol Oncol

  6. KNISELY A, Huang Y, Melamed A, Tergas AI, et al
    Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
    PubMed         Abstract available

  7. GLEESON M, Kentwell M, Meiser B, Do J, et al
    The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
    PubMed         Abstract available

    Hum Pathol

  8. TOMOHIRO M, Matsumoto T, Miura R, Oguri Y, et al
    Alterations in beta-catenin, microsatellite instability, and HNF-1beta levels are independently associated with ovarian endometriosis-associated tumorigenesis.
    Hum Pathol. 2019 Apr 22. pii: S0046-8177(19)30066.
    PubMed         Abstract available

    Obstet Gynecol

  9. LUGO SANTIAGO N, Smith E, Cox M, Wan CS, et al
    Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
    Obstet Gynecol. 2020;135:1270-1274.
    PubMed         Abstract available

    Oncol Rep

  10. PEI Y, Li K, Lou X, Wu Y, et al
    miR1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2020 May 25. doi: 10.3892/or.2020.7623.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.